Zealand Pharma A/S ranks in the top quartile of its peer group, with stability as the main structural constraint. The market setup has weakened, with clear trend damage and relative performance under pressure.
Peer-relative scores, weakest to strongest
Zealand Pharma A/S develops biopharmaceutical therapies focused on metabolic diseases, with a particular emphasis on GLP-1 and peptide-based treatments.
Zealand Pharma is priced as a GLP-1 story, not a biotech bet. The market treats 62% revenue growth as sector-leading momentum and clear confirmation of the GLP-1 franchise, but prices every step in regulatory progress directly into the stock—each approval or setback triggers immediate repricing. With its focus on GLP-1 and peptide therapies and a strong pipeline that amplifies regulatory leverage, the market reacts to each update with pronounced price swings: 1Y volatility at 54.3% puts the stock in the top decile for event risk. A single regulatory setback in GLP-1 is enough for a sharp rerating.
Break down ZEAL.CO's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.